The Cure Rate of COVID-19 Patients with Comorbid Hypertension
Abstract
Introduction: Coronavirus Disease 2019 (COVID-19) is an outbreak that has resulted in a global pandemic. In 2020, 185 countries were affected, and more than 3,000,000 cases have been reported worldwide, with more than 210,000 deaths. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2), an RNA virus that can cause respiratory system disorders. Hypertension, commonly called high blood pressure, is a health problem that often occurs in the community because its prevalence is relatively high throughout the world. Approximately 7.5 million deaths, or 12.8% of all annual deaths in the world, are caused by hypertension. Generally, the presence of comorbid hypertension in COVID-19 can worsen the patient's condition. Methods:
This literature review study aims to determine the recovery rate of COVID-19 patients with comorbid hypertension. Journals in this literature review used three databases, including Google Scholar, PubMed, and Science Direct, using the keywords COVID-19 with Hypertension and COVID-19 with Hypertension. The literature search was adjusted based on the inclusion and exclusion criteria. Results: The search results obtained 25 journals consisting of 4 national journals and 21 international journals. The results showed that the average recovery rate for COVID-19 patients with comorbid hypertension was 75.40%. Factors influencing the recovery rate of COVID-19 patients with comorbid hypertension include ACE-2, ACEI/ARBs, age, male, and cytokines. Conclusions: It can be concluded that the presence of comorbid hypertension affects the recovery rate of COVID-19 patients.
References
1. Dwi Rachmayana AM, Rahman A, Jusuf EC. Maternal Referral Profile Before and During the Covid-19 Pandemic at the Educational Hospital and Affiliation Hospital in Makassar City 2019 - 2021. Nusantara Medical Science Journal. Published online October 21, 2022:106-113. doi:10.20956/nmsj.v7i2.19873
2. Oley MH, Oley MC, Kepel RE, Kepel BJ, Tuwongkesong R, Faruk M. The Quality of Life of quarantine patients in a COVID-19 Emergency Hospital. Gazzetta Medica Italiana Archivio per le Scienze Mediche. 2024;183(6). doi:10.23736/S0393-3660.23.05289-0
3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. Published online 2020.
4. Suciangto W, Rasyid H, Nasrum NIR, Rahmani MZ. The Potential of Rosuvastatin in Stabilizing Lipid Profile and Improving Clinical Outcomes in Covid-19 Patients with Coronary Heart Disease. Nusantara Medical Science Journal. Published online October 21, 2021:54-65. doi:10.20956/nmsj.v6i1.12243
5. Oley MH, Oley MC, Kepel BJ, et al. ICAM-1 levels in patients with covid-19 with diabetic foot ulcers: A prospective study in southeast asia. Annals of Medicine and Surgery. 2021;63:102171. doi:10.1016/j.amsu.2021.02.017
6. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A. COVID-19 and Cardiovaskular Disease. Circulation. 2020;14:1648-1655.
7. Massi MN, Sjahril R, Halik H, et al. Sequence analysis of SARS-CoV-2 Delta variant isolated from Makassar, South Sulawesi, Indonesia. Heliyon. 2023;9(2):e13382. doi:10.1016/j.heliyon.2023.e13382
8. Massi MN, Abidin RS, Farouk AE, et al. Full-genome sequencing and mutation analysis of SARS-CoV-2 isolated from Makassar, South Sulawesi, Indonesia. PeerJ. 2022;10:e13522. doi:10.7717/peerj.13522
9. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. International Journal Infectious Disease. 2016;49:129-133.
10. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell Press. 2020;181:1-10.
11. Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J. A comparative study on the clinical features of coronavirus 2019 (COVID-19) pneumonia with other pneumonias. Clinical Infectious Disease. 2020;71:756-761.
12. Singh S, Shankar R, Singh GA. Prevalence and Associated Risk Factors of Hypertension: A Cross-Sectional Study in Urban Varanasi. Int J Hypertens. 2017;17.
13. Tabrizi Mf, H.Sadeghi-Bazargani Ln, ZNikniaz. Prevalence and associated factors of prehy- pertension and hypertension in Iranian population: the lifestyle promotion project (LPP. PLoS One. 2016;11(10).
14. JNC. The Seventh Report on the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health, U.S. Department of Health and Human Services; 2014.
15. Guan WJ, Ni ZY, H Y, Al E. ChinaMedical Treatment Expert Group for Covid-19. Clinical characteristics of Coronavirus disease 2019 in China. New England Journal Med. 2020;382:1708-1720.
16. Grasselli G, ZA ZA. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. Published online 2020.
17. Emami A, Javanmardi F, Akbari A, Kojuri J, Bakhtiari H, Rezaei T. Survival rate in hypertensive patients with COVID-19. Clin Exp Hypertens. 2020;1–4.
18. Rodilla E, Saura A, Jiménez I, Mendizábal A, Pineda-Cantero A, Lorenzo-Hernández E. Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19. J Clin Med. 2020;9(10):31-36.
19. Huang S, Wang J, Liu F, Liu J, Cao G, Yang C. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertension Research. Published online 2020.
20. Hasanah N, Wahyudi R. Analisis Prevalensi Komorbid dengan Kematian Pasien Covid-19 di Kabupaten Bangkalan. Published online 2021.
21. Abayomi A, Osibobogun A, Okafor OK, Idris J, Bowale A, Wright O. Morbidity and mortality outcomes of COVID-19 patients with and without hypertension in Lagos, Nigeria: a retrospective cohort study. Glob Health Res Policy. Published online 2021.
22. Moftakhar L, Piraee E, Mohammadi Abnavi M, Moftakhar P, Azarbakhsh H, Valipour A. Epidemiological Features and Predictors of Mortality in Patients with COVID-19 with and without Underlying Hypertension. Int J Hypertens. 2021;2021.
23. Zhang Y, Sha T, Wu F, Hu H, Chen Z, Li H. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. Int Heart J. 2021;62(2):337-343.
24. Wang L, He W, Yu X, Hu D, January BMS. Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. Published online 2020.
25. Zhong L, Wu Y, Gao J, Zhang J, Xie Q, He H. Effects of hypertension on the outcomes of COVID-19: a multicentre retrospective cohort study. Ann Med. 2021;53(1):770-776.
26. Fang H, Liu Q, Xi M, Xiong D, He J, Luo P. Impact of comorbidities on clinical prognosis in 1280 patients with different types of COVID-19. Journal of Investigative Medicine. 2021;69(1):75-85.
27. Deng Y, Liu W, Liu K, Fang YY, Shang J, Zhou L. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan. Chin Med J (Engl). 2020;133(11):1261-1267.
28. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-1062.
29. Osibogun A, Abayomi A, Kanma-Okafor O, Idris J, Bowale A, Wright O. Morbidity and mortality outcomes of COVID-19 patients with and without hypertension in Lagos, Nigeria: a retrospective cohort study. Glob Health Res Policy. 2021;6(1).
30. Iaccarino G, Grassi G, Borghi C, Ferri C, Salvetti M, Volpe Massimo M. Age and multimorbidity predict death among COVID-19 Patients: Results of the SARS-RAS study of the Italian society of hypertension. Hypertension. 2020;76(2):366-372.
31. Amiruddin AT, Nurdin H, Arif SK, Musba AMT, Salahuddin A, Infeksi PAS. Hubungan Penanda Infeksi, Penanda Oksigenasi, dan Faktor Risiko Lainnya terhadap Mortalitas Pasien COVID-19 dengan Pneumonia Saat Admisi di Unit Perawatan Intensif RSUP Dr. Wahidin Sudirohusodo. JAI (Jurnal Anestesiologi Indonesia). 2021;13(2):114-124.
32. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. The BMJ. 2020;368(December 2019):1-14.
33. Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. Journal of Community Empowerment for Health. 2020;3(2).
34. Widjaja JT, Kwee L, Giantara AK, Suabgiyo HA, Edwin C, Putri RL. Karakteristik Pasien COVID-19 Rawat Inap di RS Immanuel Bandung, Indonesia. Journal of Medicine and Health. 2021;3(2):164-175.
35. Drew C, Adisasmita AC. Gejala dan komorbid yang memengaruhi mortalitas pasien positif COVID-19 di Jakarta Timur, Maret-September 2020. Tarumanagara Medical Journal. 2021;3(2):274-283.
36. Khan MS, Dogra R, Miriyala LK V, Salman FNU, Ishtiaq R, Patti DK. Clinical characteristics and outcomes of patients with Corona Virus Disease 2019 (COVID-19) at Mercy Health Hospitals. PLoS One. 2021;16(4 April):1-11.
37. Cheng X, Cai G, Wen X, Gao L, Jiang D, Sun M. Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19. Aging. 2020;12(23):23436-23449.
38. Basu A, Agwu JC, Barlow N, Lee B. Hypertension is the major predictor of poor outcomes among inpatients with COVID-19 infection in the UK: A retrospective cohort study. BMJ Open. 2021;11(6).
39. Yao Q, Ni J, Hu TT, Cai ZL, Zhoo JH, Xie QW. Clinical characteristics and outcomes in coronavirus disease 2019 (COVID-19) hypertension: a retrospective study. Rev Cardiovasc Med. 2020;21(4):517-530.
40. Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41(22):2058-2066.
41. Pan W, Zhang J, Wang M, Ye J, Xu Y, Shen B. Clinical Features of COVID-19 in Patients with Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients. Hypertension. 2020;732–41.
42. Felber R, New W, Riskin SI. SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway. Cureus. Published online March 5, 2024. doi:10.7759/cureus.55563
43. Luo D, Bai M, Zhang W, Wang J. The possible mechanism and research progress of ACE2 involved in cardiovascular injury caused by COVID-19: a review. Front Cardiovasc Med. 2024;11. doi:10.3389/fcvm.2024.1409723
44. Zheng M. ACE2 and COVID-19 Susceptibility and Severity. Aging Dis. 2022;13(2):360. doi:10.14336/AD.2021.0805
45. Fagyas M, Bánhegyi V, Úri K, et al. Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients. Geroscience. 2021;43(5):2289-2304. doi:10.1007/s11357-021-00467-2
46. Zhang P. Association of inpatient use of angiotensin convert- ing enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circulation Respiratory. 2020;12(126):1168-1671.
47. Ghelmani Y, Fallah Tafti T, Shamsi F. The Effect of Age-Threshold on COVID-19 Patients Cure Rate: A Historical Cohort Study. Journal of Kerman University of Medical Sciences. 2023;30(3):171-176. doi:10.34172/jkmu.2023.28
48. Valero-Bover D, Monterde D, Carot-Sans G, et al. Is Age the Most Important Risk Factor in COVID-19 Patients? The Relevance of Comorbidity Burden: A Retrospective Analysis of 10,551 Hospitalizations. Clin Epidemiol. 2023;Volume 15:811-825. doi:10.2147/CLEP.S408510
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Made Widiantara Giri, I Made Subhawa Harsa
This work is licensed under a Creative Commons Attribution 4.0 International License.
